Skip to main content
ALGORAE PHARMACEUTICALS LIMITED logo

ALGORAE PHARMACEUTICALS LIMITED — Investor Relations & Filings

Ticker · 1AI ISIN · AU0000296022 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,159 across all filing types
Latest filing 2009-12-20 Regulatory Filings
Country AU Australia
Listing ASX 1AI

About ALGORAE PHARMACEUTICALS LIMITED

https://algoraepharma.com/

Algorae Pharmaceuticals Limited is a biopharmaceutical company focused on the discovery and development of novel therapeutic solutions for complex medical conditions. The company leverages its proprietary artificial intelligence platform, AlgoraeOS, to streamline the drug discovery process and identify synergistic drug combinations. Its research pipeline primarily targets neurodegenerative diseases and other areas of high unmet clinical need. Key development programs include AI-116, a combination therapy aimed at treating dementia and Alzheimer's disease. By integrating advanced computational modeling with traditional pharmacological research, the company seeks to accelerate the transition of candidates from preclinical stages to clinical trials, optimizing therapeutic efficacy and safety profiles.

Recent filings

Filing Released Lang Actions
LCT signs new research collaboration and option agreement 2 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a company announcement dated 21 December 2009 from Living Cell Technologies Limited. It announces a new research collaboration and option agreement to license encapsulation technology. The content focuses on business development and partnership details, with no financial statements, regulatory filings, or detailed financial performance data. It is not a report, earnings release, or regulatory filing but a corporate announcement about a collaboration agreement. Therefore, it fits best under the category of a general company announcement related to business updates, which aligns with the Regulatory Filings (RNS) category as a fallback for miscellaneous announcements that do not fit other specific categories.
2009-12-20 English
LCT extends SPP closing date until 17 December 2009 2 pages ?Kb
Capital/Financing Update Classification · 95% confidence The document is a company announcement from Living Cell Technologies Limited regarding the extension of the Share Purchase Plan (SPP) closing date. It discusses shareholder opportunities and recent developments related to the company's technology and regulatory environment. There are no financial statements, detailed financial performance data, or comprehensive report content. The document is an update on a capital raising activity (SPP extension), which fits the category of Capital/Financing Update (CAP). The document length is 5541 characters, which is sufficient for a detailed announcement but does not contain a full financial report or earnings release. Therefore, the appropriate classification is CAP with high confidence.
2009-12-10 English
LCT considers Australian trials following lifting of ban 3 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a company announcement from Living Cell Technologies Limited dated 10 December 2009. It discusses the lifting of a regulatory ban on animal cell transplantation in Australia and the company's plans to expand clinical trials there. The content focuses on regulatory developments, company plans, and scientific context rather than financial results, management changes, or shareholder voting. There are no financial statements, earnings data, or detailed management reports. The document is a public announcement about regulatory and clinical trial developments, not a formal financial or regulatory filing. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is not a report publication announcement since it does not mention the release of a report. The best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous company announcements and regulatory updates that do not fit other categories. The document length (6836 characters) supports it being a full announcement rather than a brief notice.
2009-12-09 English
LCT Clinical Trial Release 2 pages ?Kb
Regulatory Filings Classification · 85% confidence The document is a company announcement from Living Cell Technologies Limited reporting on the progress of a clinical trial for their DIABECELL product in New Zealand. It provides updates on the first patient treated, clinical observations, and future trial plans. The content is focused on clinical trial progress and public communication rather than financial results, regulatory filings, or management changes. There is no indication of financial data, earnings, board changes, or regulatory certifications. The document is a public announcement about clinical trial progress, which does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. It is not a report publication announcement since it does not mention the release or availability of a report. Given the nature of the content, the best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2009-12-03 English
Director`s Participation in the SPP 2 pages ?Kb
Capital/Financing Update Classification · 95% confidence The document is a company announcement from Living Cell Technologies Limited dated December 3, 2009, regarding a Share Purchase Plan (SPP). It states that all eligible directors have taken up the offer and provides the closing date for the SPP. The document includes contact information and a company description but does not contain financial statements, detailed financial analysis, or regulatory filings. It is a brief announcement about a capital raising activity (share purchase plan) rather than a full report or detailed financial disclosure. The document length is 4678 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the most appropriate classification is Capital/Financing Update (CAP), as it relates to company fundraising activities through a share purchase plan.
2009-12-02 English
Change of Director`s Interest Notice 4 pages ?Kb
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a director, including the number of shares and options held before and after the change, the nature of the interest, and the date of change. This type of document is a formal notification of personal share transactions by a company director. It does not contain financial performance data, audit information, or other report content. Therefore, it fits the definition of a Director's Dealing report.
2009-11-24 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.